Dr. Reddy's Laboratories Limited has submitted a regulatory disclosure under SEBI Listing Regulation 30. This communication serves as a follow-up to the company's previous intimation dated August 14, 2026, regarding a Good Manufacturing Practices (GMP) inspection conducted by the United States Food & Drug Administration (USFDA).
The inspection was conducted at the company's formulations manufacturing facility, identified as FTO-3, located in Bachupally, Hyderabad.
The USFDA has now classified the outcome of this inspection as 'Voluntary Action Indicated' (VAI). The regulatory authority has concluded the inspection and officially closed it under the provision 21 CFR 20.64(d)(3).
The disclosure, signed by K Randhir Singh (Company Secretary, Compliance Officer & Head-CSR), is submitted for information and record purposes. No financial impact or further action requirements are stated in the disclosure.